Products
Pre-made Omalizumab benchmark antibody ( Whole mAb, anti-IGHE/IgE therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-398
Pre-Made Omalizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Omalizumab, sold under the brand name Xolair, is a medication used to treat asthma, nasal polyps, and urticaria.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-398-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Omalizumab biosimilar, Whole Mab: Anti-IGHE/IgE therapeutic antibody |
| INN Name | Omalizumab |
| Target | IGHE |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL |
| 99% SI Structure | 5g64:IM:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2000 |
| Year Recommended | 2001 |
| Companies | Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis |
| Conditions Approved | Allergic asthma;Urticaria |
| Conditions Active | Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis |
| Conditions Discontinued | Hypersensitivity;Peanut hypersensitivity |
| Development Tech | na |
<